Statin therapy and lipoprotein(a) levels: a systematic review and meta-analysis
de Boer LM, Oorthuys AOJ, Wiegman A, Langendam MW, Kroon J, Spijker R, Zwinderman AH, Hutten BA
European journal of preventive cardiology · 134 citas
Etiquetas de revisión
Financiación no declaradaDatos neutrales que nuestra revisión registró sobre cómo se hizo este estudio. Describen el método, nunca si nos gusta el resultado.
Cómo se estudió
- Diseño
- Metaanálisis (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
Quién lo pagó
- Financiación
- Financiación no declarada
Publicación
- Publicado
- 2021-10-07 · Eur J Prev Cardiol · vol. 29 · número 5 · págs. 779–792
- Editorial
- Oxford University Press
- Citado
- 180 citas · más que el 99% de estudios similares · 6.5× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 77 trabajos
- Acceso
- Acceso abierto (revista híbrida) · CC-BY-NC
- Áreas de investigación
- Lipoproteins and Cardiovascular Health · Cholesterol and Lipid Metabolism · Cancer, Lipids, and Metabolism
- Palabras clave
- statins, lipoprotein(a), LDL cholesterol, cardiovascular risk, placebo comparison, cardiovascular risk reduction
- MeSH
- humans, cardiovascular diseases, cholesterol, lipoprotein(a), hydroxymethylglutaryl-coa reductase inhibitors, cholesterol, ldl
8 autores
- Lotte M. de Boer🇳🇱Amsterdam University Medical Centers; Amsterdam Cardiovascular Sciences; University of Amsterdam
- Anna O. J. Oorthuys🇳🇱Amsterdam University Medical Centers; University of Amsterdam
- Albert Wiegman🇳🇱Amsterdam University Medical Centers; University of Amsterdam
- Miranda W. Langendam🇳🇱Amsterdam Public Health; Amsterdam University Medical Centers; University of Amsterdam
- Jeffrey Kroon🇳🇱Amsterdam University Medical Centers; Amsterdam Cardiovascular Sciences; University of Amsterdam
- René Spijker🇳🇱Amsterdam Public Health; Amsterdam University Medical Centers; University of Amsterdam
- Aeilko Having Zwinderman🇳🇱Amsterdam Public Health; Amsterdam University Medical Centers; University of Amsterdam
- Barbara A. Hutten🇳🇱 · autor de correspondenciaAmsterdam University Medical Centers; Amsterdam Cardiovascular Sciences; University of Amsterdam
Resumen
El texto original del estudio, en el idioma en que se publicó.
Aims
Lipoprotein(a) [Lp(a)] is a causal and independent risk factor for cardiovascular disease (CVD). People with elevated Lp(a) are often prescribed statins as they also often show elevated low-density lipoprotein cholesterol (LDL-C) levels. While statins are well-established in lowering LDL-C, their effect on Lp(a) remains unclear. We evaluated the effect of statins compared to placebo on Lp(a) and the effects of different types and intensities of statin therapy on Lp(a).
Methods and results
We conducted a systematic review and meta-analysis of randomized trials with a statin and placebo arm. Medline and EMBASE were searched until August 2019. Quality assessment of studies was done using Cochrane risk-of-bias tool (RoB 2). Mean difference of absolute and percentage changes of Lp(a) in the statin vs. the placebo arms were pooled using a random-effects meta-analysis. We compared effects of different types and intensities of statin therapy using subgroup- and network meta-analyses. Certainty of the evidence was determined using GRADE (Grading of Recommendations, Assessment, Development, and Evaluation). Overall, 39 studies (24 448 participants) were included. Mean differences (95% confidence interval) of absolute and percentage changes in the statin vs. the placebo arms were 1.1 mg/dL (0.5-1.6, P < 0.0001) and 0.1% (-3.6% to 4.0%, P = 0.95), respectively (moderate-certainty evidence). None of the types of statins changed Lp(a) significantly compared to placebo (very low- to high-certainty evidence), as well as intensities of statin therapy (low- to moderate-certainty evidence).
Conclusion
Statin therapy does not lead to clinically important differences in Lp(a) compared to placebo in patients at risk for CVD. Our findings suggest that in these patients, statin therapy will not change Lp(a)-associated CVD risk.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial (CC BY-NC).
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.